Date: Jul 23, 2024 12:00 PM - 01:30 PM
Fee
$0.00
CE Hours
1.50
CE Units
0.150
Registration closes on Jul 29, 2024 10:00 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacist
Accreditation(s)
![Accreditation Council for Pharmacy Education](https://hurxce.learningexpressce.com/assets/accreditation/ACPE-logo_highresblack.png)
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Registration Closed
Registration Closed
Objectives
- Describe the common causes and relative risk of venothromboembolism (VTE) in persons living with human immunodeficiency virus (PLWH).
- Identify and discuss the pharmacotherapy and formulary management considerations for the FDA-approved direct- acting oral anticoagulants (DOACs) including dabigatran, rivaroxaban, apixaban and endoxaban.
- Given a clinical case of a PLWH with a diagnosis of VTE, outline pharmaceutical care actions needed to promote safe and effective management of a DOAC including dosing, drug interaction management, transitions of care and bleeding.
Speaker(s)/Author(s)
Dr. Christopher Keeys, Pharm.D.,BCPS, Pharm.D., BCPS
|
Activity Number
0010-9999-24-044-L01-P
Date:
07/23/24
Time:
12:00 PM - 01:30 PM
CE Hours
1.50
Registration Closed